Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int J Biol Macromol ; 261(Pt 1): 129537, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38278383

RESUMO

Injectable hydrogels are gaining prominence as a biocompatible, minimally invasive, and adaptable platform for cartilage tissue engineering. Commencing with their synthesis, this review accentuates the tailored matrix formulations and cross-linking techniques essential for fostering three-dimensional cell culture and melding with complex tissue structures. Subsequently, it spotlights the hydrogels' enhanced properties, highlighting their augmented functionalities and broadened scope in cartilage tissue repair applications. Furthermore, future perspectives are advocated, urging continuous innovation and exploration to surmount existing challenges and harness the full clinical potential of hydrogels in regenerative medicine. Such advancements are crucial for validating the long-term efficacy and safety of hydrogels, positioning them as a promising direction in regenerative medicine to address cartilage-related ailments.


Assuntos
Hidrogéis , Engenharia Tecidual , Engenharia Tecidual/métodos , Hidrogéis/farmacologia , Hidrogéis/química , Cartilagem , Medicina Regenerativa , Reagentes de Ligações Cruzadas/química
2.
Heliyon ; 9(5): e15583, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-37153438

RESUMO

Abnormal bone metabolism and subsequence osteoporotic fractures are common complications of chronic inflammatory diseases. No effective treatment for these bone-related complications is available at present. The chronic inflammatory state in these diseases has been considered as a key factor of bone loss. Therefore, the combination of inflammation inhibition and bone loss suppression may be an important strategy for reducing bone damage associated with inflammatory diseases. Bushen Huoxue Decoction (BSHXD) is a traditional Chinese herbal compound that has demonstrated the ability to improve bone quality and increase bone density. However, the efficacy of BSHXD on inflammatory bone loss and its underlying mechanisms remain unclear. This study aimed to investigate whether BSHXD inhibits inflammatory bone loss in mice and its potential molecular mechanisms. In the present study, the effect of BSHXD on lipopolysaccharide (LPS)-induced M1 polarization of RAW264.7 macrophage and on local inflammatory bone loss model of mouse skull was determined. The results showed that after treating RAW264.7 cells with LPS for 24 h, the expression levels of IL-1ß (39.42 ± 3.076 ng/L, p < 0.05), IL-6 (49.24 ± 1.766 mg/L, p < 0.05) and TNF-α (286.3 ± 27.12 ng/L, p < 0.05) were significantly increased. The addition of BSHXD decreased the expression levels of IL-1ß, IL-6, and TNF-α to 31.55 ± 1.296 ng/L, 37.94 ± 0.8869 mg/L, and 196.4 ± 25.25 ng/L, respectively (p < 0.05). The results of immunofluorescence staining, Western blotting (WB) and flow cytometry indicated that the proportion of M1 macrophages in RAW264.7 cells treated with BSHXD for 24 h was significantly lower than that in the LPS group (13.36% ± 0.9829% VS 24.80% ± 4.619%, p < 0.05). The evidence from in-vitro experiments showed that the immunomodulatory ability of BSHXD may be associated with the activation of AMP-dependent protein kinase (AMPK) pathway in LPS-treated macrophages. In addition, the results of micro-CT, H&E staining, immunohistochemical staining and immunofluorescence staining of mouse skull further demonstrated that BSHXD treatment significantly alleviated LPS-induced local bone loss and inflammatory damage in mouse skull model. All results indicated that BSHXD significantly inhibited inflammatory factors release and M1 polarization of macrophage through AMPK signaling pathway. Therefore, BSHXD may be a promising drug for the treatment of inflammatory bone loss.

3.
Medicine (Baltimore) ; 99(21): e20234, 2020 May 22.
Artigo em Inglês | MEDLINE | ID: mdl-32481298

RESUMO

BACKGROUND: The prevalence of chronic kidney disease (CKD) has been rapidly increasing and has become one of the most concerned global health problems. It is of good importance to improve therapeutic efficiency of CKD and delay disease progression to end stage renal disease (ESRD). Traditional Chinese Medicine (TCM) is a widely used complementary therapy for patients with CKD. The aim of this study is to evaluate whether basic treatment combined with Chinese herbs mixture Qi Gui Yi Shen decoction could achieve better therapeutic effect on CKD patients. METHODS: To determine whether traditional Chinese medicine Qi Gui Yi Shen decoction could achieve better therapeutic effect, we will conduct a randomized controlled trial. A total of 100 CKD patients that meet the inclusion criteria will be enrolled and divided into 2 groups: Qi Gui Yi Shen group (QGYS group) and placebo group. Each group will receive 6-monthly basic treatment in combination with TCM or placebo 3 times per day. Efficacy of Qi Gui Yi Shen decoction is evaluated by analyzing renal function and TCM symptoms, other efficacy assessments include serum level of PAI-I, expression of transforming growth factor beta1 (TGF-beta1). Routine blood count, plasma albumin (ALB), and alanine transaminase (ALT) are evaluated as side effect and safety profile. DISCUSSION: The results from the clinical trial will provide evidence for the effectiveness and safety of Qi Gui Yi Shen Decoction as a treatment for CKD patients. Furthermore, this will propose a new theory and method for CKD treatment. TRIAL REGISTRATION: Registered with Chinese Clinical Trials Registry at www.chictr.org. (Registration number: ChiCTR1900021622) on 1 March 2019.


Assuntos
Terapia Combinada/métodos , Medicina Tradicional Chinesa/métodos , Insuficiência Renal Crônica/tratamento farmacológico , Adolescente , Adulto , Idoso , Alanina Transaminase/sangue , Estudos de Casos e Controles , Progressão da Doença , Feminino , Humanos , Falência Renal Crônica/prevenção & controle , Masculino , Medicina Tradicional Chinesa/efeitos adversos , Pessoa de Meia-Idade , Placebos/administração & dosagem , Prevalência , Insuficiência Renal Crônica/sangue , Insuficiência Renal Crônica/epidemiologia , Insuficiência Renal Crônica/fisiopatologia , Segurança , Albumina Sérica/análise , Fator de Crescimento Transformador beta1/sangue , Adulto Jovem
4.
Artigo em Inglês | MEDLINE | ID: mdl-28920758

RESUMO

This study was conducted to investigate the pollutant status and the retention mechanism of polycyclic aromatic hydrocarbons (PAHs) in soils and sediment from bank-water-level-fluctuating zone (WLFZ)-water systems in Hanfeng Lake, Three Gorges, China. The concentrations of the 16 PAHs ranged from 21.8 to 1324 ng g-1 dry wt for all 20 soil and sediment samples. These concentration levels were remarkably lower than those in soils and sediment collected domestically and worldwide. PAHs with two and three rings were found to be dominant in all the samples, with phenanthrene being most abundant. The spatial distribution of PAHs in bank soil, WLFZ soil, and sediment implied that the transfer and fate of PAHs in the bank soil-WLFZ soil-sediment systems were influenced by both water dynamic factors and physicochemical properties of PAHs. Diagnostic ratio analysis and principal component analysis suggested that the PAHs in the areas of Hanfeng Lake were primarily (>75%) derived from coal combustion and vehicle emissions . Use of natural gas, improving gasoline/diesel quality and phasing out old and nonstandard vehicles and ships are proposed to control PAH contamination and protect drinking water safety in the region.


Assuntos
Monitoramento Ambiental/métodos , Sedimentos Geológicos/química , Lagos/química , Hidrocarbonetos Policíclicos Aromáticos/análise , Poluentes do Solo/análise , Solo/química , China , Carvão Mineral/análise , Gasolina/análise , Análise de Componente Principal , Emissões de Veículos/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA